BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $241,991 | +80563.7% | 3,555 | -3.0% | 0.01% | -15.4% |
| Q2 2023 | $300 | +7.1% | 3,665 | -2.9% | 0.01% | +8.3% |
| Q1 2023 | $280 | -25.5% | 3,775 | -16.9% | 0.01% | -29.4% |
| Q4 2022 | $376 | -99.9% | 4,540 | +275.2% | 0.02% | 0.0% |
| Q3 2022 | $343,000 | -23.6% | 1,210 | -6.6% | 0.02% | -19.0% |
| Q2 2022 | $449,000 | -21.2% | 1,295 | -1.5% | 0.02% | -4.5% |
| Q1 2022 | $570,000 | -25.3% | 1,315 | -10.8% | 0.02% | -18.5% |
| Q4 2021 | $763,000 | +3.5% | 1,475 | -3.0% | 0.03% | -3.6% |
| Q3 2021 | $737,000 | +4.2% | 1,520 | -3.2% | 0.03% | +3.7% |
| Q2 2021 | $707,000 | +16.5% | 1,570 | -1.3% | 0.03% | +12.5% |
| Q1 2021 | $607,000 | +6.1% | 1,590 | -11.7% | 0.02% | 0.0% |
| Q4 2020 | $572,000 | +17.9% | 1,800 | -8.0% | 0.02% | +9.1% |
| Q3 2020 | $485,000 | -10.4% | 1,957 | -4.4% | 0.02% | -18.5% |
| Q2 2020 | $541,000 | -21.8% | 2,047 | -43.9% | 0.03% | -34.1% |
| Q1 2020 | $692,000 | -23.8% | 3,649 | -11.7% | 0.04% | -10.9% |
| Q4 2019 | $908,000 | +4.6% | 4,133 | -6.8% | 0.05% | -2.1% |
| Q3 2019 | $868,000 | -19.3% | 4,433 | -14.1% | 0.05% | -19.0% |
| Q2 2019 | $1,075,000 | -8.7% | 5,158 | -13.0% | 0.06% | -9.4% |
| Q1 2019 | $1,177,000 | -17.7% | 5,928 | -40.0% | 0.06% | -26.4% |
| Q4 2018 | $1,431,000 | -35.9% | 9,883 | -9.5% | 0.09% | -25.6% |
| Q3 2018 | $2,231,000 | -50.6% | 10,926 | -64.2% | 0.12% | -53.6% |
| Q2 2018 | $4,519,000 | -5.5% | 30,542 | -3.5% | 0.25% | -8.0% |
| Q1 2018 | $4,782,000 | +10.3% | 31,659 | -5.4% | 0.27% | +15.6% |
| Q4 2017 | $4,336,000 | +1.6% | 33,468 | -5.2% | 0.24% | -2.9% |
| Q3 2017 | $4,269,000 | -8.9% | 35,312 | -11.4% | 0.24% | -12.5% |
| Q2 2017 | $4,685,000 | +12.8% | 39,869 | -2.4% | 0.28% | +11.2% |
| Q1 2017 | $4,152,000 | -1.8% | 40,851 | -0.6% | 0.25% | -5.3% |
| Q4 2016 | $4,228,000 | -8.5% | 41,118 | -2.6% | 0.26% | -8.9% |
| Q3 2016 | $4,623,000 | -3.7% | 42,218 | -0.8% | 0.29% | -4.6% |
| Q2 2016 | $4,801,000 | +17.9% | 42,575 | -1.2% | 0.30% | +16.4% |
| Q1 2016 | $4,073,000 | +4.0% | 43,092 | -1.0% | 0.26% | +6.9% |
| Q4 2015 | $3,917,000 | -2.9% | 43,522 | -0.3% | 0.24% | -5.0% |
| Q3 2015 | $4,036,000 | -6.4% | 43,648 | -0.4% | 0.26% | +2.8% |
| Q2 2015 | $4,314,000 | -3.4% | 43,804 | -1.6% | 0.25% | -1.2% |
| Q1 2015 | $4,467,000 | +7.8% | 44,537 | -0.7% | 0.25% | +9.0% |
| Q4 2014 | $4,143,000 | – | 44,833 | – | 0.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |